Menu
Search
|

Menu

Close
X

Natera Inc NTRA.OQ (NASDAQ Stock Exchange Global Select Market)

9.43 USD
+0.11 (+1.18%)
As of 8:05 PM IST
chart
Previous Close 9.32
Open 9.34
Volume 748
3m Avg Volume 46,748
Today’s High 9.43
Today’s Low 9.34
52 Week High 14.69
52 Week Low 7.38
Shares Outstanding (mil) 53.22
Market Capitalization (mil) 761.62
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.86 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY17
157
FY16
217
FY15
190
EPS (USD)
FY17
-1.711
FY16
-1.846
FY15
-1.438
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
3.74
5.77
Price to Book (MRQ)
vs sector
14.96
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
98.26
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-112.97
14.43
Return on Equity (TTM)
vs sector
-118.87
16.13

EXECUTIVE LEADERSHIP

Matthew Rabinowitz
Chairman of the Board, President, Chief Executive Officer, Co-Founder, Since 2015
Salary: $452,625.00
Bonus: --
Jonathan Sheena
Co-Founder, Chief Technology Officer, Director, Since 2007
Salary: $321,000.00
Bonus: --
Michael Brophy
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Roelof Botha
Lead Independent Director, Since 2007
Salary: --
Bonus: --
Todd Cozzens
Independent Director, Since 2007
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Medical Equipment, Supplies & Distribution
Address:

201 Industrial Rd Ste 410
SAN CARLOS   CA   94070-2396

Phone: +1650.2499090

Natera, Inc. is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father(s).

SPONSORED STORIES